Ropivacaine is a new aminoamide local anaesthetic. Compared with bupivacaine, ropivacaine possesses a higher threshold for systemic toxicity and a high selectivity for sensory fibres. We have compared prospectively these two agents in a concentration of 0.25 % for extradural analgesia in labour. A total of 104 parturients requesting extradural analgesia were randomized to receive either ropivacaine or bupivacaine. The women in the bupivacaine group required more top-up doses to maintain analgesia (median 3.0 vs 2.0) (P : 0.05). The onset of sensory block, quality of analgesia, ultimate level of maximum sensory block and maternal satisfaction were similar in both groups. The incidence, intensity and duration of motor block were slightly but not significantly less in the ropivacaine group. The ropivacaine group had a higher incidence of spontaneous vaginal delivery (70.59 % vs 52.00 %). There was no significant difference in neonatal outcome as assessed by Apgar scores, umbilical acid-base status and neurological and adaptive capacity score at 2 and 24 h after delivery. We conclude that ropivacaine and bupivacaine in a concentration of 0.25 % produced comparable analgesia for pain relief of labour with no detectable adverse effect on the neonate. (Br.
Extradural block is an effective means of providing analgesia in labour. However, all local anaesthetics used to date have significant disadvantages. For example, motor block results in decreased maternal mobility and satisfaction with the technique and may contribute to delay in the second stage of labour [1, 2] and postpartum backache [3] . Sympathetic block on the other hand may cause hypotension.
Serious maternal cardiotoxicity has been reported in the USA after inadvertent i.v. injection of bupivacaine [4] . Cardiac arrest, if it occurs, is resistant to treatment and has resulted in maternal deaths [5] , although this has not been reported in the UK. In contrast, lignocaine is described as less cardiotoxic than bupivacaine [6] . Top-up doses are less likely to cause late decelerations in fetal heart rate [7] and its duration of action is shorter than that of bupivacaine. Repeated doses result in cumulative toxicity and tachyphylaxis. Scanlon and colleagues [8] suggested that lignocaine, administered extradurally, can result in the birth of "floppy but alert" babies (although his findings have been refuted by others) [7, 9, 10] .
Recent attempts have been made to overcome these problems using either infusions of local anaesthetic rather than intermittent boluses [9, 11] or mixtures of dilute local anaesthetics with opioids [12] [13] [14] . There is no evidence of maternal benefit from using bupivacaine as the sole agent in extradural infusions and indeed extradural infusions of bupivacaine may result in more fetal heart rate decelerations than intermittent top-up doses [11] .
Ropivacaine is a new aminoamide local anaesthetic with a structure closely related to bupivacaine and mepivacaine. Unlike bupivacaine (which is a racemic mixture), ropivacaine is a single enantiomer. It is the S isomer of N-propyl pipecholyl xylidine. Modern racemic local anaesthetics tend to be vasodilators at high and vasoconstrictors at lower concentrations. Ropivacaine is a vasoconstrictor over a wide range of concentrations [15] .
In preclinical studies, ropivacaine was shown to have less central nervous and cardiovascular system toxicity than bupivacaine [16] [17] [18] . Ropivacaine is less lipid soluble than bupivacaine [19] but has similar protein binding. Its duration of action after extradural administration has been reported as being only slightly less than that of bupivacaine [20] but its shorter systemic half-life should make repeated doses potentially safer [21] . It has greater selectivity for sensory fibres compared with other local anaesthetics and consequently should be associated with less motor block [16, 22] . In addition, inadvertent i.v. injection is likely to produce less cardiac sequelae compared with bupivacaine, but the threshold for convulsions is similar [23] .
All of these properties suggest that ropivacaine may be superior to bupivacaine in obstetric analgesia and we have examined this hypothesis in the present study.
Patients and methods
The study was conducted at two centres with similar procedures. Approval was obtained from the hospital Ethics Committees. Written informed consent was obtained from the patients before onset of painful labour. We studied 104 healthy women, aged 18 yr or more, requesting extradural analgesia.
All patients were in established labour and had a singleton healthy pregnancy (36-42 weeks' gestation) with a vertex presentation and a healthy fetal heart rate pattern on cardiotocography. Patients were excluded if the mother had been given more than a single dose of pethidine 125 mg, was greater than 110 kg in weight, less than 150 cm tall, expected fetal weight was : 2.5 kg or the fetus had a suspected abnormality.
Patients were allocated randomly to one of two groups. Group A received bolus doses of 0.25 % ropivacaine and group B bolus doses of 0.25 % bupivacaine. The drugs were in coded ampoules and the investigators were blinded to the contents. The randomization process was stratified to take into account parity of the patients. Nulliparous parturients received numbers starting from 1 and multiparous parturients from 80 downwards.
An i.v. infusion was established and at least 500 ml of Hartmann's solution was given before extradural block. With the mother in either the sitting or left lateral position, an extradural catheter was inserted in the lumbar region using the loss of resistance technique; 2-3 cm of catheter was left in the extradural space. A test dose of 5 ml of study drug was administered via the extradural catheter. Two minutes later another 5 ml was given. If analgesia was inadequate, the patient received an additional 5 ml of drug extradurally 10 min later.
Subsequently, top-up doses of 10 ml were administered as necessary by the midwife. The minimum time between top-ups was 15 min. The maximum amount of study drug a patient could receive was 95 ml, which corresponded to eight top-up doses. The maximum amount allowed in any 3-h period was 70 ml.
Hypotension was defined as systolic arterial pressure :90 mm Hg or a reduction in arterial pressure 930 mm Hg. A hypotensive episode was treated by increasing the rate of the i.v. infusion, positioning the patient on her left side and, if necessary, administering ephedrine. Uterine activity was monitored with an external abdominal transducer and fetal heart rate was recorded using either a scalp electrode or an external ultrasound detector. Oxytocin infusion and Entonox were given as appropriate during the study.
Onset of analgesia was assessed using a pain relief score with each contraction following the initial topup (1 : no relief; 2 : little relief; 3 : a lot of relief; 4 : complete relief). A score of 3 or 4 was considered satisfactory. Assessment was discontinued when the patient decided analgesia was satisfactory. In addition, a visual analogue pain score (VAS) was recorded before extradural analgesia and then every 15 min until the infant was born.
Assessment of both sensory and motor block was made every 30 min using either ice or ethyl chloride and the Bromage score, respectively. Measurements were continued until return of normal sensation and motor function (Bromage motor score of 0).
The duration of the first and second stages of labour, mode of delivery and birth weight were recorded. In addition, Apgar scores were recorded at 1 and 5 min and umbilical arterial and venous blood samples were obtained at delivery from a clamped section of cord for assessment of PO2 and pH.
Neurological and adaptive capacity (NAC) scores were recorded at 1.5-2.5 h and 22-26 h after birth. All of these observations were performed by the research fellow in each centre. The NAC score gives a numerical score with a maximum of 40, and an NAC score .35 is considered to denote a vigorous baby [24] .
Patients were withdrawn from the study if analgesia was not satisfactory, the maximum dose of local anaesthetic allowed by the study design was exceeded, the study lasted more than 24 h or delivery was by rotational forceps or Caesarean section.
The mothers and babies were visited daily during their hospital stay and any adverse events were recorded. A general assessment of overall satisfaction with the technique was also recorded. Further follow-up was made by letter or telephone 2-3 weeks after delivery.
STATISTICAL ANALYSIS
Two approaches to the statistical analysis were used: a "per design" analysis and an "all patients treated" analysis. The "per design" (PD) approach was used for analysis of efficacy and the "all patients treated" (APT) approach for analysis of safety.
Data on an interval or ordinal scale were analysed using the stratified Wilcoxon (mid) rank sum test, adjusting for each centre and parity. Analysis of variance was used to check for interaction between strata. P values correspond to two-sided tests and P : 0.05 was considered significant. Results are expressed as median (Q1/Q3) unless otherwise stated.
Results
A total of 104 women who requested extradural analgesia for labour were recruited (52 received ropivacaine, 52 bupivacaine). One patient was withdrawn because of technical difficulties (bupivacaine group). Thus we obtained data from 103 patients (ropivacaine 52, bupivacaine 51). Of these 103 women, only 102 received the entire first dose of study drug (one woman (ropivacaine) delivered after the test dose). An additional patient (bupivacaine) delivered before analgesia had occurred after the first dose. Thus 101 patients remained who satisfactorily received analgesia after the full first dose (ropivacaine 51, bupivacaine 50). For statistical analysis, 103 patients were valid for safety analysis (APT) and 101 for efficacy analysis (PD). Another 17 women (ropivacaine eight, bupivacaine nine) discontinued the study prematurely (appendix). By far the commonest reason for withdrawal was delivery by Caesarean section.
The two groups were well matched in characteristics, parity and number of women who received one dose of pethidine before entering the study (eight ropivacaine, 10 bupivacaine) (table 1). Mean pre-anaesthetic i.v. infusion volumes were similar for each group: ropivacaine (n : 52) 653.85 (SD 233.02) (range 500-1000) ml; bupivacaine (n : 51) 676.47 (241.32) (500-1000) ml. There was no difference between the groups in the use of Entonox during labour (six ropivacaine, five bupivacaine).
MATERNAL EFFECTS

Top-ups
Eighteen percent of patients in the bupivacaine group required six or more top-ups compared with 7.8 % in the ropivacaine group (table 2). The bupivacaine group required significantly more topups (3 vs 2) (P : 0.05) (Wilcoxon rank sum test) to achieve analgesia.
The mean total doses of study drug were: ropivacaine (n : 52) 37. Duration of treatment ranged from 0 to 864 min for the ropivacaine patients (n : 52) and from 11 to 710 min for the bupivacaine group (n : 51) (ns).
Pain relief
Time to onset of pain relief was 2-59 min (ropivacaine) (n : 51) and 1-64 min (bupivacaine) (n : 50) with a median onset time of 12 min (ropivacaine) and 10.5 min (bupivacaine) (ns).
Mean individual VAS scores assessed at each contraction after treatment began until the end of the first stage of labour were similar for each group: ropivacaine (n : 51) 20.94 (10.00-30.69) (0.61-50.00) mm; bupivacaine (n : 50) 15.59 (8.91-26.90) (0.75-62.68) mm. There was no difference between the treatment groups in duration of action of each top-up (table 3) .
Quality of analgesia was assessed the day after delivery in 92 patients and described by most as either excellent or good; 91.1 % (ropivacaine), 95.4 % (bupivacaine). No patient described pain relief as poor.
Upper segmental level of analgesia was assessed in 101 patients. The median level was T8 for both groups (range T3-T11 for ropivacaine (n : 51) and T2-T11 for bupivacaine (n : 50)). Motor block was assessed in 100 patients. The treatment groups did not differ in maximum motor block during the study period (table 4) . However, 20 patients in the ropivacaine group failed to experience any motor weakness compared with 12 in the bupivacaine group (ns). The median duration for those with block was shorter in the ropivacaine (n : 28) 100. Women who received ropivacaine had an incidence of unassisted vaginal delivery (36 women) of 70.59 % compared with 52.0 % for the bupivacaine group (26 women) (ns). The number delivered by nonrotational low forceps in the bupivacaine group was 12 (24.00 %) compared with six (11.77 %) in the ropivacaine group (ns).
The remaining babies were delivered either by Caesarean section (five (9.8 %) ropivacaine, six (12 %) bupivacaine); vacuum extraction (three (5.9 %) ropivacaine; five (10.0 %) bupivacaine); or mid or high forceps (one (1.96 %) ropivacaine; one (2.00 %) bupivacaine (ns)).
FETAL EFFECTS
Birth weights for the groups were similar: ropivacaine (n = 52) 3410 g (Q1, Q3 3110, 3665 g) (range 2560-4650 g); bupivacaine (n : 49) 3400 g (3160, 3900 g) (2360-4470 g).
There was no difference between the groups in the condition of the neonate at delivery or at 24 h, as assessed by Apgar score, umbilical cord acid-base status and NAC scores, respectively (table 5) .
Adverse events were classified as mild, moderate or severe. There were 66 maternal events (ropivacaine 37; bupivacaine 29). The majority (42) were mild (ropivacaine 23, bupivacaine 19). Mild events ranged from paraesthesia with extradural catheter insertion, cardiovascular alteration, poor/failed progression of labour, Caesarean section, postnatal depression and postpartum infective episodes such as cystitis or upper respiratory tract infection. The commonest single events were paraesthesia (seven cases) with insertion of the extradural catheter, and backache after delivery (seven cases). All patients either recovered spontaneously or had improved by the 2-3-week follow-up. Those women who delivered ultimately by Caesarean section (10) were classified as adverse events (nine maternal, one fetal).
Moderate events again included poor or failed progression of labour. In addition, events such as retrosternal pain, diarrhoea, tachycardia, nausea and vomiting, and vaginal and uterine haemorrhage were classified as moderate. One event was described as severe (uterine haemorrhage in the bupivacaine group). The patient had no long-term sequelae.
In the fetuses, 60 events were reported (31 ropivacaine, 29 bupivacaine): 50 % were described as mild (16 ropivacaine, 14 bupivacaine) . With the exception of one patient (bupivacaine), these were cases of fetal bradycardia. Another 19 episodes of bradycardia were reported (12 moderate, seven severe).
Sixteen adverse events were described in the neonates (six ropivacaine, 10 bupivacaine). Similarly, the majority were mild (three ropivacaine, nine bupivacaine). The commonest event reported was jaundice (seven cases). All neonates recovered spontaneously.
Discussion
Ropivacaine should possess lower systemic toxicity than bupivacaine. In practice, although there is disparity between animal species in absolute cardiac and central nervous system toxicity [16, 17] , Scott and colleagues [23] predicted less cardiovascular toxicity with ropivacaine than with bupivacaine in human volunteers after i.v. administration. This was deduced from analysis of the electrocardiograph.
To date, ropivacaine has been administered in clinical practice by several routes and over a range of concentrations (0.1-1 %). It has been shown to provide comparable analgesia-anaesthesia by the extradural route as bupivacaine for a variety of surgical procedures [20, 25] , but uncertainty still exists over the relative depth of motor block with the two agents.
Our study suggested that 0.25 % ropivacaine and bupivacaine produced comparable analgesia in labour, in terms of onset, maximum level of sensory block and degree of patient satisfaction. Interestingly, bupivacaine-treated patients required more supplementary top-up doses to maintain effective analgesia.
Although there was no statistically significant difference in degree of motor block (as assessed by the Bromage score), there was a higher proportion of patients with no motor block in the ropivacainetreated group. Similarly, and possibly linked, was the finding that a greater number of women in this group had spontaneous vaginal delivery. Unfortunately, one criticism of the Bromage score is that it incorporates an assessment of degree of spread of local anaesthetic in addition to depth of motor block. A more sensitive assessment of motor function would be isometric testing. This could be performed by assessment of the abdominal wall by a quantified electromyographic method and in the lower extremities by mechano-transducers [26] . Assessment of the effect of a local anaesthetic on the fetus is always difficult and relies largely on evaluation of the infant at delivery and over the ensuing hours. Traditionally, neonatal condition has been assessed with the Apgar scoring system and umbilical cord acid-base status.
To distinguish the effects of a drug on a neonate from those caused by in utero asphyxia requires more detailed assessment. Amiel Tison and colleagues developed the NAC score for this purpose [24] . It has been shown clinically to be a valid and sensitive test for evaluating neurobehavioural performance scores when comparing general with regional anaesthesia for Caesarean section [27] . Our study failed to demonstrate any difference between the groups in NAC scores or in the acid-base status of the infant at delivery.
We conclude that 0.25 % ropivacaine and 0.25 % bupivacaine produced comparable and effective maternal pain relief in labour without detriment to the fetus.
